---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-24-000028"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:27:15.124086+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics appoints Dr. Alexander Gold to board; Dr. Olivier Litzka resigns

## Summary
- Appointed Alexander M. Gold, M.D. as Class I director and to Nominating and Corporate Governance Committee, effective June 13, 2024.
- Dr. Gold received options to purchase 44,000 shares vesting over three years; cash compensation per non-employee director program.
- Dr. Olivier Litzka resigned from board effective June 13, 2024, with no disagreement with company or management.
- Board size decreased from eight to seven following resignation and prior departure of Alexander Asam, Ph.D. on May 22, 2024.

## SEC filing metadata
- accession: 0001933414-24-000028
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000028/0001933414-24-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000028/mlys-20240613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-24-000028
- JSON: https://secwatch.observer/filing/0001933414-24-000028.json
- Plain text: https://secwatch.observer/filing/0001933414-24-000028.txt

## Key facts
- Executive change
  Olivier Litzka resigned as Director at Mineralys Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Olivier Litzka, Ph.D. informed the Board of his decision to resign from the Board, effective June 13, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000028/0001933414-24-000028-index.htm
- Executive change
  Alexander M. Gold was appointed as Class I director at Mineralys Therapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: the Board appointed Alexander M. Gold, M.D. as a member of the Board and the Nominating and Corporate Governance Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000028/0001933414-24-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.